Anglogold Ashanti PLC
F:HT3
Anglogold Ashanti PLC
F:HT3
Price:
75.36
EUR
0.99%
Market Closed
Market Cap:
€38B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Anglogold Ashanti PLC
F:HT3
|
UK |
|
S
|
Supercomnet Technologies Bhd
KLSE:SCOMNET
|
MY |
|
O
|
Orion Office Reit Inc
NYSE:ONL
|
US |
|
AVITA Medical Inc
NASDAQ:RCEL
|
US |
|
Shinyoung Securities Co Ltd
KRX:001720
|
KR |
|
A
|
Australian Unity Office Fund
ASX:AOF
|
AU |
|
Qoria Ltd
ASX:QOR
|
AU |
|
PB Holding N.V.
AEX:PBH
|
NL |
|
Bourse Direct SA
F:BD6
|
FR |
|
Aeffe SpA
MIL:AEF
|
IT |
|
No Signboard Holdings Ltd
SGX:1G6
|
SG |
|
G
|
Graphisoft Park SE Ingatlanfejleszto Europai Rt
F:GUV
|
HU |
|
Indah Prakasa Sentosa Tbk PT
IDX:INPS
|
ID |
|
Gem Diamonds Ltd
LSE:GEMD
|
UK |
|
P
|
Proactis SA
PAR:PROAC
|
FR |
|
Shanta Gold Ltd
LSE:SHG
|
GG |
|
Alzamend Neuro Inc
NASDAQ:ALZN
|
US |
|
Studio Alice Co Ltd
TSE:2305
|
JP |
|
Residential Secure Income PLC
LSE:RESI
|
UK |
|
Tengda Construction Group Co Ltd
SSE:600512
|
CN |
|
Tamburi Investment Partners SpA
MIL:TIP
|
IT |
|
E
|
Euro Cervantes SOCIMI SA
MAD:YEUR
|
ES |
|
Spexis AG
SIX:SPEX
|
CH |
|
Nova Eye Medical Ltd
ASX:EYE
|
AU |
Income Statement
Earnings Waterfall
Anglogold Ashanti PLC
Anglogold Ashanti PLC
Income Statement
Anglogold Ashanti PLC
Anglogold Ashanti PLC
Currency: USD
| Dec-2023 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Interest Expense |
125
|
139
|
0
|
133
|
0
|
0
|
0
|
0
|
|
| Revenue |
4 582
N/A
|
4 948
+8%
|
6 439
+30%
|
5 793
-10%
|
9 247
+60%
|
9 140
-1%
|
10 066
+10%
|
9 893
-2%
|
|
| Gross Profit | |||||||||
| Cost of Revenue |
(3 551)
|
(3 603)
|
(4 553)
|
(3 723)
|
(5 796)
|
(5 242)
|
(5 517)
|
(5 019)
|
|
| Gross Profit |
1 031
N/A
|
1 345
+30%
|
1 886
+40%
|
2 070
+10%
|
3 451
+67%
|
3 898
+13%
|
4 549
+17%
|
4 874
+7%
|
|
| Operating Income | |||||||||
| Operating Expenses |
(423)
|
(481)
|
(619)
|
(446)
|
(744)
|
(699)
|
(727)
|
(653)
|
|
| Selling, General & Administrative |
(100)
|
(116)
|
(136)
|
(121)
|
(165)
|
(133)
|
(145)
|
(138)
|
|
| Research & Development |
(254)
|
(247)
|
(319)
|
(252)
|
(375)
|
(324)
|
(324)
|
(267)
|
|
| Other Operating Expenses |
(69)
|
(118)
|
(164)
|
(73)
|
(204)
|
(242)
|
(258)
|
(248)
|
|
| Operating Income |
608
N/A
|
864
+42%
|
1 267
+47%
|
1 624
+28%
|
2 707
+67%
|
3 199
+18%
|
3 822
+19%
|
4 221
+10%
|
|
| Pre-Tax Income | |||||||||
| Interest Income Expense |
55
|
143
|
147
|
95
|
74
|
7
|
37
|
146
|
|
| Non-Reccuring Items |
(568)
|
(414)
|
(427)
|
(13)
|
40
|
68
|
78
|
(91)
|
|
| Total Other Income |
(32)
|
(27)
|
(27)
|
(34)
|
(26)
|
(13)
|
(13)
|
0
|
|
| Pre-Tax Income |
63
N/A
|
566
+798%
|
960
+70%
|
1 672
+74%
|
2 795
+67%
|
3 261
+17%
|
3 924
+20%
|
4 276
+9%
|
|
| Net Income | |||||||||
| Tax Provision |
(285)
|
(512)
|
(672)
|
(623)
|
(970)
|
(951)
|
(1 033)
|
(1 102)
|
|
| Income from Continuing Operations |
(222)
|
54
|
288
|
1 049
|
1 825
|
2 310
|
2 891
|
3 174
|
|
| Income to Minority Interest |
(13)
|
(18)
|
(29)
|
(45)
|
(155)
|
(282)
|
(417)
|
(538)
|
|
| Net Income (Common) |
(235)
N/A
|
36
N/A
|
259
+619%
|
1 004
+288%
|
1 670
+66%
|
2 028
+21%
|
2 474
+22%
|
2 636
+7%
|
|
| EPS (Diluted) |
-0.56
N/A
|
0.08
N/A
|
0.61
+663%
|
2.33
+282%
|
3.31
+42%
|
4
+21%
|
4.84
+21%
|
5.19
+7%
|
|
Switch to:
Switch to:
See Also
Discover More
